Impact of system updates for sensor‐augmented pump therapy on glycemic management in Japanese individuals with type 1 diabetes ( SAP ‐J T1D study)

Aims/Introduction Sensor‐augmented pump (SAP) therapy has evolved sequentially, but long‐term clinical evidence supporting these advances has remained limited. We here evaluated the impact of updates to SAP therapy on glycemic outcomes in individuals with type 1 diabetes. Methods This retrospective observational study (SAP‐J T1D) included Japanese individuals with type 1 diabetes receiving SAP therapy. Treatment efficacy of the MiniMed 620G, 640G, and 770G systems (Medtronic) was evaluated at three predefined time points: baseline (before the switch from 620G to 640G), before the switch from 640G to 770G, and 1 year after the switch to 770G. The primary outcome was the change in time in range (TIR) for continuous glucose monitoring from baseline to 1 year after the transition to the MiniMed 770G system. Results A total of 47 participants were included in the analysis. The median age was 45 years (interquartile range, 33–56 years), and the median body mass index was 22.3 kg/m 2 (20.4–23.7 kg/m 2 ). TIR increased progressively with each system update, from 69.0% (61.5–75.5%) with MiniMed 620G, to 72.0% (63.5–79.0%) with MiniMed 640G, and to 77.0% (73.0–80.5%) with MiniMed 770G. Time below range decreased after the switch to MiniMed 640G, whereas time above range decreased after that to MiniMed 770G. Time in tight range increased after the transition to the MiniMed 770G system. Conclusions Sequential updates in SAP therapy were associated with stepwise improvements in glycemic management, reflecting the distinct functional characteristics of each system.